DE602004017005D1 - A1 adenosin-rezeptor-antagonisten - Google Patents
A1 adenosin-rezeptor-antagonistenInfo
- Publication number
- DE602004017005D1 DE602004017005D1 DE602004017005T DE602004017005T DE602004017005D1 DE 602004017005 D1 DE602004017005 D1 DE 602004017005D1 DE 602004017005 T DE602004017005 T DE 602004017005T DE 602004017005 T DE602004017005 T DE 602004017005T DE 602004017005 D1 DE602004017005 D1 DE 602004017005D1
- Authority
- DE
- Germany
- Prior art keywords
- sub
- optionally substituted
- sup
- mammal
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101150007969 ADORA1 gene Proteins 0.000 title 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 2
- 108050000203 Adenosine receptors Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000008085 renal dysfunction Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48946903P | 2003-07-22 | 2003-07-22 | |
| PCT/US2004/023632 WO2005009445A1 (en) | 2003-07-22 | 2004-07-22 | A1 adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004017005D1 true DE602004017005D1 (de) | 2008-11-20 |
Family
ID=34102883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004017005T Expired - Lifetime DE602004017005D1 (de) | 2003-07-22 | 2004-07-22 | A1 adenosin-rezeptor-antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7022710B2 (enExample) |
| EP (1) | EP1646390B1 (enExample) |
| JP (1) | JP2006528199A (enExample) |
| KR (1) | KR20060037383A (enExample) |
| AT (1) | ATE410168T1 (enExample) |
| CA (1) | CA2533402A1 (enExample) |
| DE (1) | DE602004017005D1 (enExample) |
| WO (1) | WO2005009445A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
| US20080280926A1 (en) * | 2003-12-16 | 2008-11-13 | Palle Venkata P | Phosphodiesterase Inhibitors |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| ES2361886T3 (es) * | 2006-06-27 | 2011-06-24 | Cbt Development Limited | Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina. |
| WO2009052310A1 (en) * | 2007-10-16 | 2009-04-23 | Cv Therapeutics, Inc | A3 adenosine receptor antagonists |
| BRPI0909157A2 (pt) * | 2008-03-26 | 2015-11-24 | Advinus Therapeutics Private Ltd | compostos heterocíclicos como antagonistas de receptores de adenosina |
| DE102008039083A1 (de) * | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
| US20130109645A1 (en) | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
| DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19816857A1 (de) * | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6545002B1 (en) * | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| DK1208100T3 (da) * | 1999-08-31 | 2003-06-30 | Univ Vanderbilt | Selektive antagonister af A2B adenosinreceptorer |
| KR20020042248A (ko) * | 2000-11-30 | 2002-06-05 | 한가람 | 문장으로부터의 감정 인식 및 표시 방법과 시스템 |
| EP1401837B1 (en) * | 2001-06-29 | 2005-10-19 | Cv Therapeutics, Inc. | Purine derivatives as a2b adenosine receptor antagonists |
| WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
| US7968523B2 (en) | 2001-07-23 | 2011-06-28 | Senesco Technologies, Inc. | Method for inducing apoptosis using apoptosis-specific EIF5-A |
| AU2002361374A1 (en) * | 2001-12-21 | 2003-07-09 | JSW-Research Forschungslabor GmbH% | Pyrazolyl-substituted triazoloquinoxalines |
-
2004
- 2004-07-22 WO PCT/US2004/023632 patent/WO2005009445A1/en not_active Ceased
- 2004-07-22 KR KR1020067001373A patent/KR20060037383A/ko not_active Ceased
- 2004-07-22 JP JP2006521248A patent/JP2006528199A/ja active Pending
- 2004-07-22 CA CA002533402A patent/CA2533402A1/en not_active Abandoned
- 2004-07-22 AT AT04778924T patent/ATE410168T1/de not_active IP Right Cessation
- 2004-07-22 US US10/897,047 patent/US7022710B2/en not_active Expired - Fee Related
- 2004-07-22 EP EP04778924A patent/EP1646390B1/en not_active Expired - Lifetime
- 2004-07-22 DE DE602004017005T patent/DE602004017005D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE410168T1 (de) | 2008-10-15 |
| CA2533402A1 (en) | 2005-02-03 |
| HK1093422A1 (en) | 2007-03-02 |
| WO2005009445A1 (en) | 2005-02-03 |
| US20050059683A1 (en) | 2005-03-17 |
| JP2006528199A (ja) | 2006-12-14 |
| EP1646390A1 (en) | 2006-04-19 |
| US7022710B2 (en) | 2006-04-04 |
| EP1646390B1 (en) | 2008-10-08 |
| KR20060037383A (ko) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2204920T3 (es) | Guanidinas substituidas terapeuticas. | |
| EP1438973A1 (en) | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | |
| MY147451A (en) | 4-phenyl-pyridine derivatives and their use as nk-1 receptor antagonists | |
| WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
| SK282566B6 (sk) | Deriváty benzimidazolu, farmaceutický prostriedok a použitie | |
| JPWO1994014769A1 (ja) | Ｎ−置換インドール誘導体 | |
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| KR0139626B1 (ko) | 강심제 | |
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| ATE410168T1 (de) | A1 adenosin-rezeptor-antagonisten | |
| ES2170859T3 (es) | Derivados de imidazol 1h-4(5)-sustituidos. | |
| JP2007523909A5 (enExample) | ||
| RU2011149635A (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаина | |
| JP2006504738A5 (enExample) | ||
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| PL178054B1 (pl) | Związki 7-(2-imidazolinyloamino)chinolinowe przydatne jako agoniści alfa-2-adrenoceptorów i kompozycja farmaceutyczna zawierająca związek 7-(2-imidazolinyloamino) chinolinowy i nośnik,przydatna do leczenia zaburzeń dróg oddechowych | |
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| AR126976A1 (es) | Compuesto antagonista del receptor de la endotelina a (eta), y método de preparación y aplicaciones médicas del mismo | |
| BRPI0414663A (pt) | derivados triazol substituìdos como antagonistas de oxitocina | |
| RU2005137155A (ru) | Производные 9-азабицикло [3.3.1] нон-6-ена с гетероатомом на позиции 3 как ингибиторы ренина | |
| RU2005137184A (ru) | Новые производные тропана | |
| NO20021879D0 (no) | Bisykliske vasopressinagonister | |
| NO20053715L (no) | 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk | |
| CA2402099A1 (en) | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment | |
| JP2006528199A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |